利民股份(002734) - 2019 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2019 was ¥396,577,307.05, representing a 9.86% increase compared to ¥360,968,689.79 in the same period last year[7] - Net profit attributable to shareholders was ¥82,549,278.89, a significant increase of 40.63% from ¥58,697,775.43 in the previous year[7] - The net profit after deducting non-recurring gains and losses was ¥79,867,853.66, up 42.96% from ¥55,869,195.94 year-on-year[7] - The basic earnings per share increased to ¥0.3, reflecting a 42.86% rise from ¥0.21 in the same quarter last year[7] - The total operating revenue for Q1 2019 was CNY 396,577,307.05, an increase of 9.5% compared to CNY 360,968,689.79 in the same period last year[34] - The total operating costs for Q1 2019 amounted to CNY 349,464,069.99, up from CNY 319,791,295.35, reflecting a year-over-year increase of 9.3%[34] - The net profit attributable to the parent company for Q1 2019 was CNY 41,175,289.21, compared to CNY 23,261,967.82 in the previous year, indicating a significant increase in profitability[34] - The net profit for Q1 2019 reached CNY 84,357,900.52, compared to CNY 59,309,252.06 in the same period last year, representing an increase of approximately 42.3%[36] - The total profit for Q1 2019 was CNY 91,522,905.28, an increase from CNY 67,767,102.84 in the prior year[36] - The company's operating profit for Q1 2019 was CNY 91,597,174.85, compared to CNY 67,920,973.63 in the previous year, indicating a growth of approximately 35%[36] - The total comprehensive income for Q1 2019 was CNY 84,017,154.42, compared to CNY 58,611,842.05 in the same period last year[37] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,815,097,213.48, a 2.92% increase from ¥2,735,314,477.10 at the end of the previous year[7] - The net assets attributable to shareholders reached ¥1,899,369,983.55, marking a 4.56% increase from ¥1,816,501,857.44 at the end of the previous year[7] - The company's total assets as of March 31, 2019, were CNY 2,507,331,471.76, compared to CNY 2,463,322,329.32 at the end of 2018, representing a growth of 1.8%[33] - The total liabilities decreased to CNY 640,583,409.09 from CNY 673,806,576.54, showing a reduction of approximately 4.9%[32] - The company's equity attributable to shareholders rose to CNY 1,866,748,062.67 from CNY 1,789,515,752.78, marking an increase of 4.3%[33] Cash Flow - The net cash flow from operating activities was negative at -¥98,643,992.52, a decline of 118.39% compared to -¥45,169,290.92 in the same period last year[7] - Cash flow from operating activities decreased by 118.39% due to reduced cash receipts from sales and increased outflows for raw material purchases[14] - The cash and cash equivalents decreased to CNY 222,019,629.56 from CNY 324,518,191.57, a decline of 31.6%[30] - The ending balance of cash and cash equivalents was CNY 259.61 million, down from CNY 611.64 million at the end of the previous year[45] - Total cash outflow from operating activities was CNY 337.49 million, compared to CNY 316.89 million last year[44] - Cash outflow for investment activities was CNY 471.14 million, significantly higher than CNY 62.91 million in the previous year[45] Investment and Subsidies - The company received government subsidies amounting to ¥3,308,648.58 during the reporting period[8] - Investment income surged by 77.01% as a result of significant profit increases from associated companies[14] - The company reported an investment income of CNY 41,175,289.21, significantly higher than CNY 23,261,967.82 from the previous year, highlighting improved returns from investments[34] - The investment income from joint ventures and associates was CNY 39,756,482.70, significantly higher than CNY 13,125,027.61 in the previous year[40] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,093[10] Research and Development - Research and development expenses for Q1 2019 were CNY 10,590,308.47, slightly up from CNY 10,341,463.87, indicating continued investment in innovation[34] - The company's research and development expenses for Q1 2019 were CNY 7,334,127.18, slightly down from CNY 7,385,112.09 in the previous year[39] Other Financial Metrics - The weighted average return on equity was 4.44%, up from 3.45% in the previous year, indicating improved profitability[7] - Accounts receivable increased by 76.06% due to unendorsed bank acceptance bills and seasonal sales, leading to uncollected receivables[14] - Accounts payable rose by 70.69% mainly due to unsettled raw material procurement payments[14] - Other non-current assets increased by 38.36% due to higher prepayments for land purchases[14] - Short-term borrowings slightly increased to CNY 525,000,000.00 from CNY 520,000,000.00[26] - The company is planning a major asset restructuring involving the acquisition of 100% equity in Hebei Weiyuan Bio-Chemical Co., Ltd. and related companies[16] Audit Information - The company did not undergo an audit for the first quarter report[50]